Table 1.

Patient demographics and baseline characteristics.

	Ontamalimab 75 mg [n = 164]	Ontamalimab 225 mg [n = 166]	Ontamalimab overall [n = 330]
Mean [SD] age, years	40.5 [12.75]	41.1 [13.68]	40.8 [13.21]
Sex, n [%] male	102 [62.2]	96 [57.8]	198 [60.0]
Ethnicity, n [%] Hispanic or Latino	4 [2.4]	6 [3.6]	10 [3.0]
Race, n [%]
White	148 [90.2]	143 [86.1]	291 [88.2]
Black	3 [1.8]	2 [1.2]	5 [1.5]
Asian	11 [6.7]	15 [9.0]	26 [7.9]
Other	2 [1.2]	6 [3.6]	8 [2.4]
Mean [SD] BMI, kg/m2	25.25 [5.69]	25.24 [4.59]	25.24 [5.16]
Anti-TNF naïve, n [%]	68 [41.5]	76 [45.8]	144 [43.6]
Mean [SD] time since UC diagnosis, yearsa	8.69 [7.04]	7.56 [7.36]	8.12 [7.21]
Mean [SD] total Mayo score	6.0 [2.87]	5.9 [2.84]	6.0 [2.85]
Mean [SD] Mayo endoscopic subscore	2.2 [0.07]	2.2 [0.06]	2.2 [0.05]
Mean [SD] concentration of hsCRP [mg/dL]b	n = 160	n = 162	n = 322
	0.94 [1.266]	0.73 [0.89]	0.83 [1.10]
Mean [SD] concentration of FC [µg/g]c	n = 142	n = 155	n = 329
	2468.3 [3819.3]	1924.7 [2541.8]	2184.6 [3222.4]
Receiving systemic glucocorticoids for UC, n [%]	59 [36.0]	71 [42.8]	130 [39.4]
Smoking classification, n [%]c
Never smoked	107 [65.2]	102 [61.4]	209 [63.3]
Smoker	8 [4.9]	9 [5.4]	17 [5.2]
Ex-smoker	49 [29.9]	55 [33.1]	104 [31.5]
Clinical responder at baseline, n [%]d	79 [48.2]	75 [45.2]	154 [46.7]
Mucosal healing at baseline, n [%]	34 [20.7]	33 [19.9]	67 [20.3]

Treatment groups based on initial randomisation assignment.

BMI, body mass index; FC, faecal calprotectin; hsCRP, high-sensitivity C-reactive protein; SD, standard deviation; TNF, tumour necrosis factor; UC, ulcerative colitis.

^aCalculated as: [[date of visit 1 in TURANDOT II − date of diagnosis from TURANDOT] + 1] / 365.25.

^bCalculated for patients included in the pharmacodynamic analyses only.

^cAt screening in TURANDOT.

^dThose who achieved clinical response based on total Mayo score at Week 12 in TURANDOT.